• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Chronic kidney disease: a clinical action plan
 

Chronic kidney disease: a clinical action plan

on

  • 826 views

 

Statistics

Views

Total Views
826
Views on SlideShare
826
Embed Views
0

Actions

Likes
0
Downloads
3
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Chronic kidney disease: a clinical action plan Chronic kidney disease: a clinical action plan Document Transcript

    • Chronic kidney disease: a clinical action plan T he following data show the classification of stages of chronic kidney disease, includ- ing the population at increased risk of developing chronic kidney disease, and actions to prevent the development of chronic kidney disease and to improve outcomes in each stage. Stage Description GFR Action* (mL/min/1.73m2) At increased risk ≥90 Screening (with CKD risk factors) CKD risk reduction 1. Kidney damage ≥90 Diagnosis and treatment with normal or ↑ GFR Treatment of comorbid con- ditions, slowing progression, CVD risk reduction 2. Kidney damage 60–89 Estimating progression with mild ↓ GFR 3. Moderate ↓ GFR 30–59 Evaluating and treating complications 4. Severe ↓ GFR 15–29 Preparation for kidney replacement therapy 5. Kidney failure <15 Replacement (or dialysis) (if uremia present) Shaded area identifies patients who have chronic kidney disease; unshaded area designates individuals who are at increased risk for developing chronic kidney disease. Chronic kidney disease is defined as either kid- ney damage or GFR <60 mL/min/1.73 m 2 for 3 months. Kidney damage is defined as pathologic abnormali- ties or markers of damage, including abnormalities in blood or urine tests or imaging studies. * Includes actions from preceding stages. Source: National Kidney Foundation